Zobrazeno 1 - 10 of 61 pro vyhledávání: '"J.M.M. Gijtenbeek"'
1
Immune Checkpoint Inhibitor–related Guillain-Barré Syndrome: A Case Series and Review of the Literature
Autor: Karin H Herbschleb, Marye J Boers-Sonderen, Theresa Y S Leow, Winald R. Gerritsen, Harm Westdorp, J.M.M. Gijtenbeek, Jorien B.E. Janssen
Publikováno v: Journal of Immunotherapy (1997), 44, 7, pp. 276-282
Journal of Immunotherapy (1997), 44, 276-282
Item does not contain fulltext Immune checkpoint inhibitors (ICIs) have been approved for the treatment of various malignancies with promising clinical outcomes. Treatment can, however, be accompanied by serious immune-related adverse events. Neurolo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3994d0f03867dca7341cae9e86ae42fa
https://doi.org/10.1097/cji.0000000000000364
Zobrazit plný text záznamu
2
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial
Autor: Lale Erdem-Eraslan, Roger Stupp, Pim J. French, Th Gorlia, Gail Ryan, Olivier Chinot, F. Dhermain, J.M.M. Gijtenbeek, Monika E. Hegi, P. A. E. Sillevis Smitt, Johan M. Kros, Maaike J. Vos, Carmen Balana, M. Ben Hassel, M. E. van Linde, Gao Y, Khê Hoang-Xuan, A. von Deimling, Brigitta G. Baumert, A. A. Brandes, Bas Weenink, Roelien H. Enting, Warren P. Mason, M. J. van den Bent
Publikováno v: Gao, Y, Weenink, B, van den Bent, M J, Erdem-Eraslan, L, Kros, J M, Sillevis Smitt, P A E, Hoang-Xuan, K, Brandes, A A, Vos, M, Dhermain, F, Enting, R, Ryan, G F, Chinot, O, Ben Hassel, M, van Linde, M E, Mason, W P, Gijtenbeek, J M M, Balana, C, von Deimling, A, Gorlia, T, Stupp, R, Hegi, M E, Baumert, B G & French, P J 2018, ' Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial ', European Journal of Cancer, vol. 94, pp. 168-178 . https://doi.org/10.1016/j.ejca.2018.02.023
European Journal of Cancer
European Journal of Cancer, 2018, 94, pp.168-178. ⟨10.1016/j.ejca.2018.02.023⟩
European Journal of Cancer, 94, 168-178. Elsevier Ltd.
European Journal of Cancer, Elsevier, 2018, 94, pp.168-178. 〈10.1016/j.ejca.2018.02.023〉
European Journal of Cancer, 94, pp. 168-178
European Journal of Cancer, Elsevier, 2018, 94, pp.168-178. ⟨10.1016/j.ejca.2018.02.023⟩
European Journal of Cancer, 94, 168-178
European Journal of Cancer, 94, 168-178. Pergamon
European Journal of Cancer, 94, 168-178. ELSEVIER SCI LTD
European journal of cancer (Oxford, England, 94, 168-178. Elsevier Limited
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Introduction: The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ) chemotherapy confers survival advantage compared with radiotherapy (RT) in l
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4162fea92c3a37e28fc354eb2873bec4
https://research.vumc.nl/en/publications/58893c65-c797-4e1d-be63-f6fd69c6ec74
Zobrazit plný text záznamu
3
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
Autor: H. Wiesinger, Ulrich Bogdahn, Jacoline E C Bromberg, Alicia Tosoni, J.M.M. Gijtenbeek, Peter Hau, W.T.A. van der Graaf, Anouk Allgeier, Denis Lacombe, Marc Frenay, Mario Campone, Alba A. Brandes, Roger Stupp, Hwan Jung Yun, M. J. van den Bent, L. Breimer, Thierry Gorlia
Publikováno v: Annals of Oncology, 22, 2144-9
Annals of Oncology, 22, 9, pp. 2144-9
Annals of Oncology, vol. 22, no. 9, pp. 2144-2149
Annals of Oncology
Annals of Oncology, 22(9), 2144-2149. Elsevier Ltd.
Item does not contain fulltext BACKGROUND: Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the blood-brain barrier has demonstrated preclinical activity in glioma models. PATIENTS AND METHODS: Patients with fir
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aff761ff942a5427a762451d3bee2780
http://doc.rero.ch/record/291521/files/mdq729.pdf
Zobrazit plný text záznamu
4
Successful third-line chemotherapy for an adult with recurrent medulloblastoma
Autor: Pieter Wesseling, Filip de Vos, J.M.M. Gijtenbeek, Suzanne E. J. Kaal
Publikováno v: International Cancer Conference Journal, 3(1), 32-37. Springer Japan
de Vos, F Y, Kaal, S E, Wesseling, P & Gijtenbeek, J M 2014, ' Successful third-line chemotherapy for an adult with recurrent medulloblastoma ', International Cancer Conference Journal, vol. 3, no. 1, pp. 32-37 . https://doi.org/10.1007/s13691-013-0111-0
Medulloblastoma is a rare tumor in adults. There is no standard treatment, and extrapolation of treatment results from the pediatric population is flawed by differences in behavior of the tumor and in tolerance of treatment at different ages. In this
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c494dfe0f404d397a400c74cc681d0b
https://doi.org/10.1007/s13691-013-0111-0
Zobrazit plný text záznamu
5
P01.037 Quality criteria for glioma care, use in clinical practice: results of a national survey
Autor: F. Y.F.L. de Vos, K Dujardin, J.M.M. Gijtenbeek, M A de Peuter, H P Bienfait, Maaike J. Vos, M. C. J. Hanse, L van Baest, Vincent K Y Ho
Publikováno v: Neuro-Oncology. 20:iii236-iii237
BACKGROUND: The Dutch Society for Neuro-Oncology (LWNO) in collaboration with the patients’ association, developed quality criteria for glioma care. The criteria encompass the phases of diagnosis, treatment and follow-up. Following the approval of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::497c005b8d34f6ee5683e76c547b3fb5
https://doi.org/10.1093/neuonc/noy139.079
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas
Autor: Filip de Vos, J.M.M. Gijtenbeek, Carla M.L. van Herpen, Chantal P. Bleeker-Rovers
Publikováno v: Critical Reviews in Oncology Hematology, 85, 373-82
Critical Reviews in Oncology Hematology, 85, 3, pp. 373-82
Item does not contain fulltext High-grade glioma patients receiving concomitant chemoradiotherapy with temozolomide 75mg/m(2) during six to seven weeks or dose-dense temozolomide regimens especially in combination with chronic use of corticosteroids
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26db1b5a578839fed65324da5928bd93
https://doi.org/10.1016/j.critrevonc.2012.08.002
Zobrazit plný text záznamu
9
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Autor: Tzahala Tzuk-Shina, Gail Ryan, Monika E. Hegi, Jacoline E C Bromberg, Olivier Chinot, Johan M. Kros, Warren P. Mason, Andreas von Deimling, Martin J. van den Bent, Jeremy Rees, Alba A. Brandes, Jaap C. Reijneveld, Mohamed Ben Hassel, Denis Lacombe, Sebastian Kurscheid, Khê Hoang-Xuan, Roelien H. Enting, Loïc Feuvret, Carmen Balana, Wolfgang Wick, Thierry Gorlia, Brigitta G. Baumert, Martin J.B. Taphoorn, David Capper, Robert A Nordal, Roger Stupp, Michele Reni, J.M.M. Gijtenbeek, Paul Clement, Frédéric Dhermain, Jose Bravo-Marques, Nicolas Dif, John P. Rossiter, Christine Marosi, Brian Thiessen, Guy Kantor, Christian Hartmann
Publikováno v: Lancet. Oncology, vol. 17, no. 11, pp. 1521-1532
The Lancet Oncology, 17(11), 1521-1532
Lancet oncology, 17(11), 1521-1532. Elsevier Science
Baumert, B G, Hegi, M E, van den Bent, M J, von Deimling, A, Gorlia, T, Hoang-Xuan, K, Brandes, A A, Kantor, G, Taphoorn, M J B, Hassel, M B, Hartmann, C, Ryan, G, Capper, D, Kros, J M, Kurscheid, S, Wick, W, Enting, R, Reni, M, Thiessen, B, Dhermain, F, Bromberg, J E, Feuvret, L, Reijneveld, J C, Chinot, O, Gijtenbeek, J M M, Rossiter, J P, Dif, N, Balana, C, Bravo-Marques, J, Clement, P M, Marosi, C, Tzuk-Shina, T, Nordal, R A, Rees, J, Lacombe, D, Mason, W P & Stupp, R 2016, ' Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033) : a randomised, open-label, phase 3 intergroup study ', Lancet Oncology, vol. 17, no. 11, pp. 1521-1532 . https://doi.org/10.1016/S1470-2045(16)30313-8
Lancet Oncology, 17(11), 1521-1532. ELSEVIER SCIENCE INC
Lancet Oncology, 17, 1521-1532
lancet oncology, 17(11), 1521-1532. Lancet Publishing Group
The Lancet. Oncology
Lancet Oncology, 17(11), 1521-1532. Lancet Publishing Group
Lancet Oncology, 17, 11, pp. 1521-1532
BACKGROUND: Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting molecular heterogeneity of the disease. We compared two different, single-modality treatment strategies of standard radiotherapy versus primary temozolomide chemoth
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e910c9f844d3e6aed809411c2d28645
https://serval.unil.ch/notice/serval:BIB_360C4F8410B2
Zobrazit plný text záznamu
10
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response
Autor: Jacoline E C Bromberg, Irene van Heuvel, Winand N.M. Dinjens, Walter Taal, Martin J. van den Bent, Willem Boogerd, Floris H. Groenendijk, Tjeerd J. Postma, Johan M. Kros, Hendrikus J. Dubbink, Bronno van der Holt, Chris B.L. Zonnenberg, Ronald van Marion, Peter A. E. Sillevis Smitt, Bernard A. Zonnenberg, J.M.M. Gijtenbeek, Mathilde C.M. Kouwenhoven
Publikováno v: Neuro-Oncology, 13, 235-41
Neuro-Oncology, 13, 2, pp. 235-41
Taal, W, Dubbink, H J, Zonnenberg, C B L, Zonnenberg, B A, Postma, T J, Gijtenbeek, J M M, Boogerd, W, Groenendijk, F H, Kros, J M, Kouwenhoven, M C M, van Marion, R, van Heuvel, I, van der Holt, B, Bromberg, J E C, Smitt, P A E S, Dinjens, W N M & van den Bent, M J 2011, ' First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response ', Neuro-Oncology, vol. 13, no. 2, pp. 235-241 . https://doi.org/10.1093/neuonc/noq177
Neuro-Oncology, 13(2), 235-241. Oxford University Press
Diffuse infiltrating low-grade glioma (LGG; WHO grade II tumors) constitute approximately 10–20% of primary brain tumors in adults and primarily occur in young adults.1 The majority of LGGs are low-grade diffuse astrocytomas (LGAs). Although LGAs a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14fd98e3b5b680b0d9c016fd44f57a1f
https://doi.org/10.1093/neuonc/noq177
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje